Findings from a survey on several pharma companies unveil the best practices for monitoring indirect product contact surfaces. Walid El Azab and Lillia Belkhamassi explain. urfaces in the healthcare industry pose different levels of contamination risks based on the level of contact with the drug product. Typically, the types of surface are classified as direct, indirect, and non-product contact surfaces. Surface cleanliness monitoring must be adapted based on the potential risk to contaminate the next product. Thus, the types of surfaces selected for monitoring should be scientifically justified; a walkthrough and observation of the surfaces to analyse potential exposure to the drug product are critical to support the justification. Click Here For Complete Article Text
|
||||||||||||||||||
Application Sequencing | ||||||||||||||||||
|
||||||||||||||||||
Company | Product | Process | Other Subjects | Event | Event Date | Location | Publication | Publication Date | Text Descriptor | |||||||||
|
|
|
|
|
|
|
|
|